Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
Human EZH2 Protein expressed in HEK-293 Cells - ABIN2720645
Pedram Fatemi, Salah-Uddin, Modarresi, Khoury, Wahlestedt, Faghihi: Screening for Small-Molecule Modulators of Long Noncoding RNA-Protein Interactions Using AlphaScreen. in Journal of biomolecular screening 2015
Show all 2 Pubmed References
Study shows that the PRC2 core components are enriched in retinal progenitors and downregulated in differentiated cells. Knockdown of the PRC2 core component Ezh2 leads to reduced retinal progenitor proliferation.
EZH2-deficient hESCs can initiate differentiation toward developmental lineages; however, they cannot fully differentiate into mature specialized tissues. Thus, EZH2 is required for stable ESC self-renewal, regulation of transcriptional programs, and for late-stage differentiation in this model of early human development.
The finding that EZH2 promotes chemoresistance through SLFN11 silencing suggests that EZH2 inhibition may prevent chemoresistance in patients with SCLC and enhance the efficacy of chemotherapy.
we demonstrate a reduction in myeloma cell proliferation with EZH2 inhibition, which leads to cell cycle arrest followed by apoptosis. This is mediated via upregulation of cyclin-dependent kinase (show CDK1 Proteins) inhibitors associated with removal of the inhibitory H3K27me3 mark at their gene loci.
Results demonstrate that EZH2 and ALDH1 (show ALDH1A1 Proteins) proteins are expressed in the stromal component of phyllodes tumors (PTs (show PTS Proteins)), and that EZH2 is associated with a diagnosis of malignant PT with progression to sarcoma.
Knockdown of EZH2 abolished the function of TUG1 and suppressed cell proliferation while co-transfection of sh-EZH2 and TUG1 expression vector showed that TUG1 promoted cell proliferation inhibited by sh-EZH2.
Low EZH2 or MUS81 (show MUS81 Proteins) expression levels predict chemoresistance.
High EZH2 expression is associated with colon cancer.
EZH2 expression was significantly associated with markers of poor prognosis such as estrogen receptor (show ESR1 Proteins) negativity, progesterone receptor (show PGR Proteins) negativity and high Ki-67 (show MKI67 Proteins) proliferation index. High EZH2 expression was not correlated with the response to neoadjuvant chemotherapy. Conclusions Our data suggested that EZH2 protein expression may not correlate with the clinical response to neoadjuvant chemotherapy.
Low EZH2 expression is associated with Glioma.
Overexpression of EZH2 was found in 30 patients (76.9%) and was associated with FIGO stage, histological type, and lymph node metastasis (p < 0.05). In conclusion, our data suggest that RIPK4 (show RIPK4 Proteins)/EZH2 markers might be used as potential predictors of prognosis in cervical cancer.
Gfi1 (show ZNF163 Proteins) disruption antagonized the tumor-promoting effects of Ezh2 loss; conversely, Gfi1 (show ZNF163 Proteins) overexpression collaborated with Myc (show MYC Proteins) to bypass effects of Trp53 (show TP53 Proteins) inactivation in driving medulloblastoma progression in primary cerebellar neuronal progenitors.
we found that the miRNA biogenesis enzyme DICER was required for the binding of the PRC2 core components EZH2 and SUZ12, and for the presence of the PRC2-mediated histone modification H3K27me3 at many bivalent genes
High EZH2 expression is associated with Neuroblastoma (show ARHGEF16 Proteins).
Biochemical as well as functional experiments revealed that Spt6 could compete for binding of the PRC2 methyltransferase Ezh2 to Suz12 and reduce PRC2 chromatin engagement.
These findings indicate that Ezh2 targets are the major targets of the epigenetic switch in MDS (show MECOM Proteins) with Ezh2 insufficiency.
Insight regarding how androgen-induced extranuclear kinase signaling and intranuclear transcription through Ezh2 modifications may influence the expression pattern of genes, ultimately affecting various downstream physiological processes.
results uncover a crucial role for EZH2 in adaptive lymphocytes to control the developmental timing of effectors of the pre-Ag receptor checkpoints
These findings identify the Ezh2-Hsp90 (show HSP90 Proteins) interaction as a previously unrecognized mechanism essential for T-cell responses and an effective target for controlling graft-versus-host disease.
Eed (show EED Proteins) and Ezh2 have distinct roles in urothelial differentiation
This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Multiple alternatively splcied transcript variants encoding distinct isoforms have been identified for this gene.
enhancer of zeste 2
, enhancer of zeste homolog 2 (Drosophila)
, Polycomb protein EZH2
, histone-lysine N-methyltransferase EZH2
, histone-lysine N-methyltransferase EZH2-like
, Enhancer of zeste homolog 2-A
, Polycomb protein EZH2-A
, lysine N-methyltransferase 6
, enhancer of zeste homolog 2
, eyes absent homolog 2